DTT Data Collections Guided Search
There are numerous datasets from the NIEHS Division of Translational Toxicology (DTT). They vary in size and content consisting of both small datasets with simple formats and large datasets with complex disparate formats. The DTT Data Collections Guided Search allows public users as well as DTT scientists to access them through new guided search options. The search results are displayed as simple filterable tables and available for download.
Name | Group | Description |
---|---|---|
The ICCVAM Acute Systemic Toxicity Reference List | NICEATM | The ICCVAM in vitro basal cytotoxicity assays proposed for setting starting doses for in vivo acute oral toxicity studies. |
The NICEATM Estrogen Receptor Uterotrophic Assay Data | NICEATM | The dataset provides data on the effects of chemicals on the Estrogen Receptor (ER) from uterotrophic assays. |
The ICCVAM Skin Sensitization (Murine LLNA) Reference List | NICEATM | The dataset provides a list of recommended reference substances for validation of In Vitro Murine Local Lymph Node Assay (LLNA) for skin sensitization. |
The ICCVAM Androgen Receptor Agonist Reference List | NICEATM | The dataset provides a list of recommended reference substances for evaluation or validation of In Vitro Androgen Receptor (AR) agonism assays. |
Tox21 Phase 2 Purity | Tox21 | The purity data is for the DTT Tox21 Phase 2 chemicals provided to NCATS for the Tox21 Phase 2 program. These data results from the analysis of neat chemicals, prior to the preparation of the DMSO solutions sent to NCATS and should not be equated with NCATS QC Day 0 or QC Day 4 data. |
Bioassay Genetox Conclusion Dataset | DTT | The dataset provides DTT conclusions from bioassay level of evidence, and genetic toxicology measures of bacterial mutagenicity, micronucleus, and comet assay; February 2022 version. In TR544 and subsequent reports, for studies showing multiple chemical-related neoplastic effects that if considered individually would be assigned to different levels of evidence categories. In a study with clear evidence of carcinogenic activity at some tissue sites, other responses that alone might be deemed some evidence are indicated as “were also related” to chemical exposure. In studies with clear or some evidence of carcinogenic activity, other responses that alone might be termed equivocal evidence are indicated as “may have been” related to chemical exposure. These levels of evidence are now included in this dataset. |
Ames Conclusions | DTT | Conclusions from Ames studies for each strain, activation condition, etc. |
Toxicity Estimates of the ToxCast Chemicals in C. elegans and Zebrafish | DTT | Phase I and II C. elegans and zebrafish toxicity estimates. Developmental Effects of the ToxCast™ Phase I and Phase II Chemicals in Caenorhabditis elegans and Corresponding Responses in Zebrafish, Rats, and Rabbits. Windy A. Boyd , Marjolein V. Smith , Caroll A. Co , Jason R. Pirone , Julie R. Rice , Keith R. Shockley , and Jonathan H. Freedman. Published:01May2016. https://doi.org/10.1289/ehp.1409645. |
Microarray Dataset | DTT | Toxicogenomic studies consisting of microarrays to evaluate the biological response to a toxicological challenge at the genome level. |
Drosophila Germ Cell Mutagenicity | DTT | Conclusions from Drosophila germ cell mutagenicity studies. |
Mammalian Cell Cytogenetics | DTT | Conclusions from mammalian cell cytogenetics studies for CHO-W-B1 hamsters. |
Mammalian Cell Mutagenicity | DTT | Conclusions from mammalian cell mutagenics studies for each activation condition. |
Rodent Cytogenetics | DTT | Conclusions from rodent cytogenetics studies for B6C3F1 mice. |
In Vivo Micronucleus | DTT | Study and trial conclusions from in vivo micronucleus assays for each strain and tissue, etc. |
Statistically Analyzed DTT Pathology Lesions (with Incidence) | DTT | This dataset contains lesions found in studies where each dose group had two or more of the lesion. Lesions with a statistically significant difference (p<0.05) in incidence between the exposed and control animals are flagged. The data contained herein were collected in 2020 from a source now known to contain omissions. We plan to replace with an up to date dataset in 2023.
|
Comet Assay Conclusions | DTT | Conclusions from comet assays for each strain, organ, etc. |
Evaluation of Androgen Receptor Agonists Dataset | DTT | Evaluation of androgen assay results using a curated Hershberger database. Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS. Published: 25 May 2018. https://doi.org/10.1016/j.reprotox.2018.08.017. Performance data from applying the ToxCast/Tox 21 androgen receptor model, based on 11 high throughput assays, to 39 reference chemicals. |
Update of the 1993 database of Schaper for RD50 and corresponding TLV values* | NON_DTT | Inhalation Threshold Limit Values (TLVs) for 103 chemicals originally listed in Schaper, M. (1993), Development of a database for sensory irritants and its use in establishing occupational exposure limits, Am. Ind. Hyg. Assoc. J. 54: 488-544; doi: 10.1080/15298669391355017, were updated in 2015. Data resulting from this update are included in this data table. |
List of Chemicals with Threshold Limit Values Primarily Based on Sensory Irritation* | NON_DTT | Inhalation Threshold Limit Values (TLVs) for 112 chemicals listed in the 2015, American Conference of Governmental Industrial Hygienists (ACGIH) booklet entitled "TLVs and BEIs Based on the Documentation of the Threshold Limit Values for Chemical Substances and Physical Agents & Biological Exposure Indices". |
Evaluation of Androgen Receptor Antagonists | DTT | Evaluation of androgen assay results using a curated Hershberger database. Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS. Published: 25 May 2018. https://doi.org/10.1016/j.reprotox.2018.08.017. Performance data from applying the ToxCast/Tox 21 androgen receptor model, based on 11 high throughput assays, to 39 reference chemicals. |
Tox21 Androgen Receptor Assays and Androgen Receptor Pathway Model Dataset | DTT | Evaluation of androgen assay results using a curated Hershberger database. Kleinstreuer NC, Browne P, Chang X, Judson R, Casey W, Ceger P, Deisenroth C, Baker N, Markey K, Thomas RS. Published: 25 May 2018. https://doi.org/10.1016/j.reprotox.2018.08.017. Performance data from applying the ToxCast/Tox 21 androgen receptor model, based on 11 high throughput assays, to 39 reference chemicals. |
Hallmark Gene Sets Annotations | DTT | Annotation of Hallmark Gene Sets using NextBio platform to identify correlations between Hallmark Gene Sets and gene expression studies focusing on liver, heart and kidney tissue in rodents and humans. Additionally, correlations to gene expression studies in other tissues in rodents are described herein. |
In Vitro Micronucleus | DTT | Study and trial conclusions from micronucleus assays for each cell type and activation condition, etc. |
Identification of p53 Activators in a Human Microarray Compendium, Tox21 Positive Results | DTT | Biomarkers predictive of molecular and toxicological effects are needed to interpret emerging high-throughput transcriptomic data streams. The TGx-DDI biomarker was compared to microarray data in a compendium derived from human cells using the Running Fisher test, a nonparametric correlation test. In addition, the Tox21 p53 assay examined p53 responses at multiple doses at 16 h and in parallel identified doses that were cytotoxic. This dataset contains 19 biosets that were positive in the Tox21 Assay. |
Identification of p53 Activators in a Human Microarray Compendium with Significant Biomarker Correlation | DTT | Biomarkers predictive of molecular and toxicological effects are needed to interpret emerging high-throughput transcriptomic data streams. The TGx-DDI biomarker was compared to microarray data in a compendium derived from human cells using the Running Fisher test, a nonparametric correlation test. This dataset contains 274 biosets with a significant TGx-DDI biomarker correlation. |
Summary of Health Effects Studies of Neonicotinoid Pesticides by Evidence Stream | DTT | Data of animal biological systems affected by chemical exposure with relevance to human health effects. |
Chemicals Causing 10% or Greater Body Weight Loss in F344 Strains of Rats | DTT | Summary body weight data with ratio of the treatment group body weight mean to the control group body weight mean. |
Animal Studies Evaluating Neonicotinoid Exposures and Neurological, Developmental or Congenital Effects | DTT | Data of animal neurological and developmental/congenital outcomes from chemical exposure with relevance to human health effects. |
CEBSR: Statistically Analyzed DTT Pathology Lesions (with incidence, BMD, NEL, and LEL) | DTT | This dataset contains statistically significant lesions from DTT studies as collated in the CEBSR database, including legacy and recently reported studies. Tissue name and morphology terminology have been harmonized for this dataset. New endpoints for each lesion are available: BMD (benchmark dose), LEL (lowest effect level) and NEL (no effect level). The data contained herein were collected in 2021 from a source now known to contain omissions. We plan to replace with an up to date dataset in 2023. |
CEBSR: DTT Clinical Pathology Data | DTT | This dataset contains clinical pathology summary data from the CEBSR database, including legacy and recently reported studies. The test names and units have been harmonized for this dataset. Documentation including test name descriptions and study exclusion are available here: https://cebs.niehs.nih.gov/cebs/paper/14893. Regarding statistical analyses and interpretation of clinical pathology data: statistical analyses are a starting point in the interpretation of clinical pathology data and should not be used as a primary tool to identify test article-related effects. Statistical significance testing of clinical pathology data should not replace critical scientific interpretation of data (ideally by an experienced veterinary toxicologic clinical pathologist) and consideration of clinical and biological relevance of any observed changes. Clinical pathology data should be evaluated in context with all other available study data including in-life data (e.g., food consumption, body weight) and histopathology. For more information about statistical significance testing for clinical pathology in toxicology studies, please refer to the below listed references. Aulbach A, Vitsky A, Arndt T, et al. Overview and considerations for the reporting of clinical pathology interpretations in nonclinical toxicology studies. Vet Clin Pathol. 2019;48:389–399. https://doi.org/10.1111/vcp.12772 Hall RL. Practical Considerations in Clinical Pathology Data Interpretation and Description: The Use of Statistics, Reference Intervals, and Severity Descriptors. Toxiol Path. 2017;45:362-365. https://doi.org/10.1177/0192623316669824 Siska W, Gupta A, Tomlinson L, Tripathi N, von Beust B. Recommendations for clinical pathology data generation, interpretation, and reporting in target animal safety studies for veterinary drug development. Int J Toxicol. 2017;36:293-302. https://doi.org/10.1177/1091581817711876 |
CEBSR: DTT Clinical Pathology Control Data | DTT | This dataset contains control group clinical pathology summary data from the CEBSR database, including legacy and recently reported studies. The test names and units have been harmonized for this dataset. Documentation including test name descriptions and study exclusion are available here: https://cebs.niehs.nih.gov/cebs/paper/14893. Regarding statistical analyses and interpretation of clinical pathology data: statistical analyses are a starting point in the interpretation of clinical pathology data and should not be used as a primary tool to identify test article-related effects. Statistical significance testing of clinical pathology data should not replace critical scientific interpretation of data (ideally by an experienced veterinary toxicologic clinical pathologist) and consideration of clinical and biological relevance of any observed changes. Clinical pathology data should be evaluated in context with all other available study data including in-life data (e.g., food consumption, body weight) and histopathology. For more information about statistical significance testing for clinical pathology in toxicology studies, please refer to the below listed references. Aulbach A, Vitsky A, Arndt T, et al. Overview and considerations for the reporting of clinical pathology interpretations in nonclinical toxicology studies. Vet Clin Pathol. 2019;48:389–399. https://doi.org/10.1111/vcp.12772 Hall RL. Practical Considerations in Clinical Pathology Data Interpretation and Description: The Use of Statistics, Reference Intervals, and Severity Descriptors. Toxiol Path. 2017;45:362-365. https://doi.org/10.1177/0192623316669824 Siska W, Gupta A, Tomlinson L, Tripathi N, von Beust B. Recommendations for clinical pathology data generation, interpretation, and reporting in target animal safety studies for veterinary drug development. Int J Toxicol. 2017;36:293-302. https://doi.org/10.1177/1091581817711876 |
CEBSR: Control DTT Pathology Lesions | DTT | This dataset contains lesions from control groups in DTT studies as collated in the CEBSR database, including legacy and recently reported studies. Tissue name and morphology terminology have been harmonized for this dataset. The data contained herein were collected in 2021 from a source now known to contain omissions. We plan to replace with an up to date dataset in 2023.
|
DTT Individual Animal Pathology Lesions | DTT | This dataset contains individual animal lesions from the Division of Translational Toxicology (DTT) studies including legacy and recently reported data. Tissue name, locator, morphology, and modifier terminologies have been harmonized for this dataset. We have a current DTT dictionary available at https://doi.org/10.22427/NTP-DATA-002-00092-0002-0000-5. The terms used to develop this collection is available here: https://doi.org/10.22427/NTP-DATA-002-00092-0001-0000-4. |
Catalog of Expression Studies | DTT | Catalog of studies of Environmental Health (EH) interest with expression data performed by members of DTT, NIEHS and other collaborators. Work can be filtered using common metadata using the CEBS data collections interface. |
DTT Studies of Flame Retardants | DTT | We took as a case study the challenge to find work on flame retardants conducted by authors affiliated with the National Toxicology Program Findings: We then reviewed the abstract to identify the species, cell system, duration of exposure and assays / endpoints measured. Result – a data set listing 70 publications, 68 distinct chemicals or chemical mixtures, and 295 chemical/publication combination (i.e. a chemical listed in a publication) |
CEBS Study Catalog | DTT | This dataset provides an overview of public studies accessioned into the DTT Collection, including test compounds and standardized study factors like sex, species, strain, route, role, and vehicle. Standard terms are derived from the Data Dictionary. |
CEBS Subject Decoder | DTT | This dataset provides a mapping of individual subjects that have data occurring in multiple legacy databases. GDB is a legacy database that contains data relating to hematology, organ weights, andrology, and other clinical chemistry recorded observations (Single Point Data). TDMSE is a legacy database that contains data relating to histopathology and clinical pathology findings (Observation Data). When a subject underwent assays from both categories (Single Point Data and Observation Data), then the subjects are represented in both databases, by different unique identifiers. This dataset provides the mapping necessary to identify a single subject across single point and observation data findings. |